Immune-mediated inflammatory disease and coronary calcium: Elevated baseline risk and attenuated prognostic gradient
Abstract
Background Immune-mediated inflammatory diseases (IMID) are associated with accelerated atherosclerosis, yet it is unclear whether CT coronary artery calcium scoring (CTCS) captures this excess cardiovascular risk accurately. We hypothesized that in adults undergoing CTCS, IMID modifies the relationship between coronary artery calcium (CAC) score and incident major adverse cardiac events (MACE). Methods Among 43,420 patients in the CLARIFY Registry (University Hospitals Cleveland, 2014-2020) who underwent no-cost CTCS scans, we identified 545 IMID patients. After propensity-score matching on age, sex, race, hypertension, diabetes, and smoking status with a 2:1 ratio, 1635 matched patients were analyzed (545 with IMID and 1090 matched non-IMID controls). CAC was categorized as 0, 1–99, 100–399, ≥400. The primary outcome of 4-point MACE was analyzed over a median 4.2-year follow-up. Cox models tested CAC categories compared to CAC 0, stratified by IMID. Additionally, a log(CAC+1) × IMID interaction term was modeled, to assess whether the risk gradient of CAC differed by IMID status. Results IMID patients exhibited over twice the MACE incidence of matched controls (40.8 vs 17.6 per 1,000 person-years). Among those with zero CAC, IMID patients had a three-fold higher event rate (21.98 vs 7.18 per 1000 person-years). In controls, MACE risk rose stepwise with CAC, quadrupling from CAC 0 to ≥400 (adjusted HR = 4.74; p < 0.001), whereas in IMID patients increasing CAC conferred no significant gradient (p = 0.21). The interaction between CAC and IMID was significant (β = –0.27; HR 0.76, 95% CI 0.55–1.00), indicating an attenuated CAC-MACE relationship in IMID. Conclusion In IMID patients, baseline risk is elevated even with zero CAC, with attenuation of the traditional CAC-risk gradient observed in non-IMID controls. These findings suggest that, for IMID patients (1) a CAC score of zero may not guarantee low cardiovascular risk and (2) CAC has less incremental prognostic value than in the general population.
Fields of Study & Subjects
Inflammasome and immune disorders
Parathyroid Disorders and Treatments
Biomarkers in Disease Mechanisms
Publication details
- Journal / source
- American Journal of Preventive Cardiology
- Publisher
- Elsevier BV
- Volume
- 26
- Pages
- 101434–101434
- Publication date
- 18 January 2026
- Language
- EN